We are live on ! Find out more
SXTC icon

China SXT Pharmaceuticals
SXTC

1 hedge funds and large institutions have $2.58M invested in China SXT Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

63% less capital invested

Capital invested by funds: $6.97M → $2.58M (-$4.38M)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$88K
2
Jane Street
Jane Street
New York
-$72K
3
UBS Group
UBS Group
Switzerland
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Hudson Bay Capital Management
1
Hudson Bay Capital Management
Connecticut
$2.53M – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$25K – – –
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$19K – – –
Deutsche Bank
4
Deutsche Bank
Germany
$10K – – –
Invesco
5
Invesco
Georgia
– -$88K – –
Jane Street
6
Jane Street
New York
– -$72K – –
UBS Group
7
UBS Group
Switzerland
– -$7K – –

SXTC Hedge Fund Activity: Q3 2019 in Review

1 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q3 2019, worth a combined $2.58M — down 63% from $6.97M a quarter earlier.

Fund positioning in SXTC was balanced in Q3 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Invesco, cutting an estimated $88K.

  • 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $2.58M of China SXT Pharmaceuticals stock for Q3 2019, down 63% quarter-over-quarter.
  • 0 funds opened new China SXT Pharmaceuticals positions in Q3 2019 and 0 closed out.
  • The largest China SXT Pharmaceuticals seller in Q3 2019 was Invesco, an estimated $88K sold.

Based on aggregated 13F filings for Q3 2019.